BRAF and melanoma: In addition, no targeted therapy has been approved for BRAF-WT melanomas, despite the fact that this subgroup accounts for the majority of cases, often has activation of the MAPK pathway [14], and has an aggressive cell biology with an unfavorable prognosis [15, 16].